Loading clinical trials...
Loading clinical trials...
A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection Who Are at High Risk for RSV-related Disease Progression
Conditions
Interventions
Rilematovir
Placebo
Locations
86
United States
Central Alabama Research
Birmingham, Alabama, United States
Fiel Family and Sports Medicine Clinical Research Advantage
Tempe, Arizona, United States
IMD Clinical Trials
Bakersfield, California, United States
Hope clinical Research LLC
Canoga Park, California, United States
Peninsula Research Associates
Rolling Hills Estates, California, United States
Bensch Clinical Research, LLC
Stockton, California, United States
Start Date
November 17, 2021
Primary Completion Date
March 31, 2022
Completion Date
March 31, 2022
Last Updated
September 24, 2024
NCT07220109
NCT07092865
NCT04959734
NCT07239583
NCT05045612
NCT06984094
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions